Home > Journals > Minerva Urology and Nephrology > Past Issues > Minerva Urology and Nephrology 2022 February;74(1) > Minerva Urology and Nephrology 2022 February;74(1):29-37

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   

Minerva Urology and Nephrology 2022 February;74(1):29-37

DOI: 10.23736/S2724-6051.20.03952-1

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Comparison of multiple abbreviated multiparametric MRI-derived protocols for the detection of clinically significant prostate cancer

Lorenzo CERESER 1, Gianluca GIANNARINI 2 , Filippo BONATO 3, Stefano PIZZOLITTO 4, Giuseppe COMO 1, Claudio VALOTTO 2, Vincenzo FICARRA 5, Fabrizio DAL MORO 6, 7, Chiara ZUIANI 1, 3, Rossano GIROMETTI 1, 3

1 Institute of Radiology, Santa Maria della Misericordia Academic Medical Center, Udine, Italy; 2 Unit of Urology, Santa Maria della Misericordia Academic Medical Center, Udine, Italy; 3 Department of Medicine, Santa Maria della Misericordia Academic Medical Center, University of Udine, Udine, Italy; 4 Unit of Pathology, Santa Maria della Misericordia Academic Medical Center, Udine, Italy; 5 Section of Urology, Gaetano Barresi Department of Human and Pediatric Pathology, University of Messina, Messina, Italy; 6 Clinic of Urology, University of Udine, Udine, Italy; 7 Unit of Urology, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy



BACKGROUND: The aim of this paper was to compare the accuracy of multiple abbreviated multiparametric magnetic resonance imaging (mpMRI)-derived protocols in detecting clinically significant prostate cancer (csPCa).
METHODS: One hundred and eight men undergoing staging 3.0T mpMRI with a Prostate Imaging - Reporting and Data System version 2 (PI-RADSv2)-compliant protocol before radical prostatectomy (RP) were retrospectively evaluated. Two readers (R1, R2) independently analyzed mpMRI, assigning a PI-RADSv2 category to each observation as appearing on each examination sequence. A study coordinator assessed final PI-RADSv2 category by combining readers’ assignments according to four protocols: short MRI (sMRI) (diffusion-weighted imaging + axial T2-weighted imaging), contrast-enhanced short MRI (cesMRI) (sMRI + dynamic contrast-enhanced [DCE] imaging), biparametric MRI (diffusion-weighted imaging + multiplanar T2-weigthed imaging), and mpMRI. Using RP pathology as the reference standard for csPCa, we calculated the per-lesion cancer detection rate (CDR) and false discovery rate (FDR) for each MRI protocol (cut-off PI-RADSv2 category ≥3), and the per-PI-RADSv2 category prevalence of csPCa and false positives.
RESULTS: Pathology after RP found 142 csPCas with median International Society of Urogenital Pathology grade group 2, and stage ≤pT2c in 68.6% of cases. CDR was comparable across the four MRI protocols (74.6% to 75.3% for R1, and 68.3% for R2). FDR was comparable as well (14.4%-14.5% for R1 and 11.1% for R2). sMRI was the minimum protocol equaling mpMRI in terms of CDR, although cesMRI, similarly to mpMRI, was associated with fewer PI-RADSv2 category 3 assignments and higher prevalence of csPCa within PI-RADSv2 category 3 observations (66.7% versus 76.9% for R1, and 100% versus 91.7% for R2, respectively).
CONCLUSIONS: Among multiple abbreviated mpMRI-derived protocols, cesMRI was the one equaling mpMRI in terms of csPCa detection and minimizing PI-RADSv2 category 3 assignments.


KEY WORDS: Prostatic neoplasms; Prostatectomy; Magnetic resonance imaging; Diagnosis; Contrast media

top of page